Skip to main content

Table 2 Patient characteristics of the study population in the first and second supplementary analyses

From: Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia

 

SA-1

 

SA-2

 

4–8 weeks (n = 95)

8–12 weeks (n = 95)

4–7 weeks (n = 132)

7–12 weeks (n = 132)

Number or

mean (sd)

(%)

Number or

mean (sd)

(%)

SDif

Number or

mean (sd)

(%)

Number or

mean (sd)

(%)

SDif

Age

 

55.06 (9.29)

 

54.05 (8.20)

 

0.115

54.30 (9.13)

 

54.13 (8.54)

 

0.019

Gender

Female

7

(7)

6

(6)

0.042

9

(7)

8

(6)

0.031

Male

88

(93)

89

(94)

 

123

(93)

124

(94)

 

Residency

Non-north

52

(55)

55

(58)

0.064

76

(58)

80

(61)

0.062

North

43

(45)

40

(42)

 

56

(42)

52

(39)

 

Tumor size

≤ 5 cm

47

(49)

40

(42)

0.148

54

(41)

53

(40)

0.015

> 5 cm

48

(51)

55

(58)

 

78

(59)

79

(60)

 

Tumor differentiation

Poorly/undifferentiated

21

(22)

21

(22)

0

42

(32)

36

(27)

0.100

Well/moderately

74

(78)

74

(78)

 

90

(68)

96

(73)

 

RT delivery

Non-IGRT

71

(75)

72

(76)

0.024

103

(78)

104

(79)

0.018

IGRT

24

(25)

23

(24)

 

29

(22)

28

(21)

 

Use of PET

No

10

(11)

9

(9)

0.035

13

(10)

16

(12)

0.073

Yes

85

(89)

86

(91)

 

119

(90)

116

(88)

 

Tumor location

Cervical

0

0

Non-cervical

 

 

T-stage

T1-T2

9

(9)

12

(13)

0.101

18

(14)

16

(12)

0.045

T3-T4

86

(91)

83

(87)

 

114

(86)

116

(88)

 

N-stage

Negative

15

(16)

11

(12)

0.123

16

(12)

14

(11)

0.048

Positive

80

(84)

84

(88)

 

116

(88)

118

(89)

 

Drinking

No

13

(14)

10

(11)

0.097

16

(12)

15

(11)

0.024

Yes

82

(86)

85

(89)

 

116

(88)

117

(89)

 

Betel nut chewing

No

45

(47)

39

(41)

0.127

55

(42)

55

(42)

0

Yes

50

(53)

56

(59)

 

77

(58)

77

(58)

 

Smoking

No

18

(19)

14

(15)

0.113

18

(14)

19

(14)

0.022

Yes

77

(81)

81

(85)

 

114

(86)

113

(86)

 

BMI

 

21.85 (3.08)

 

22.17 (3.21)

 

0.104

21.83 (3.39)

 

21.80 (3.19)

 

0.009

Number of lymph nodes

< 15

19

(20)

24

(25)

0.126

33

(25)

34

(26)

0.017

≥ 15

76

(80)

71

(75)

 

99

(75)

98

(74)

 

RT dose (Gy)

 

47.03 (3.97)

 

47.49 (3.71)

 

0.120

47.56 (3.68)

 

47.85 (3.37)

 

0.080

  1. BMI body mass index, IGRT image-guided radiotherapy, nCCRT neoadjuvant concurrent chemoradiotherapy, PET positron emission tomography, RT radiotherapy, sd standard deviation, SDif standardized difference
  2. Rounded
  3. The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells ≤ 2)